BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst (Nasdaq: BCRX) announced inducement equity grants for 24 newly hired employees, comprising 251,150 stock options and 368,550 restricted stock units (RSUs) granted as of February 2, 2026, under Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $6.63 equal to the closing price on the grant date, vest in four equal annual installments beginning one year from grant, and each option has a 10-year term. Grants are subject to the Inducement Equity Incentive Plan and applicable award agreements.

Key Figures

Current share price: $6.42 New employees: 24 employees Stock options granted: 251,150 shares +5 more

8 metrics

Current share price $6.42 Prior close before inducement grant news

New employees 24 employees Granted inducement equity awards

Stock options granted 251,150 shares Aggregate options under inducement grants

RSUs granted 368,550 shares Aggregate RSUs under inducement grants

Option exercise price $6.63 per share Equal to closing price on Feb 2, 2026 grant date

Option term 10 years Duration of inducement stock options

52-week high/low $11.31 / $6.00 Trading range prior to this announcement

Daily price change -4.18% Move prior to publication of inducement grant news

Market Reality Check

Price: $6.42 Vol: Volume 4,326,701 vs 20-da...

normal vol

$6.42 Last Close

Volume Volume 4,326,701 vs 20-day average 4,952,088 (relative volume 0.87x). normal

Technical Price $6.42 trades below 200-day MA $8.21, near 52-week low of $6.00 and below high of $11.31.

Peers on Argus

BCRX was down 4.18% with peers like AVDL, HROW, PAHC and AMPH also slightly lowe...

BCRX was down 4.18% with peers like AVDL, HROW, PAHC and AMPH also slightly lower, while BGM fell 43.94%. Scanner data does not flag a coordinated sector move.

Historical Context

5 past events · Latest: Jan 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 23	Strategic acquisition	Positive	+0.6%	Completed Astria Therapeutics acquisition adding Phase 3 HAE asset and financing.
Jan 12	Revenue update	Positive	-4.2%	Preliminary 2025 ORLADEYO revenue of $601M beating prior guidance with strong growth.
Jan 06	Inducement grant	Neutral	+2.3%	Granted 18,300 RSUs as employment inducement under Nasdaq Rule 5635(c)(4).
Jan 06	Conference appearance	Neutral	+2.3%	Announced presentation at 44th Annual J.P. Morgan Healthcare Conference.
Dec 12	FDA approval	Positive	-0.1%	FDA approved ORLADEYO oral pellets for HAE prophylaxis in young pediatric patients.

Pattern Detected

Recent history shows multiple instances where positive or neutral news aligned with flat or negative price reactions, suggesting frequent divergence between fundamentals news flow and short-term moves.

Recent Company History

Over the last few months, BioCryst reported several major milestones. On Dec 12, 2025, ORLADEYO oral pellets received FDA approval for HAE patients aged 2 to under 12. In early January 2026, the company issued preliminary 2025 ORLADEYO revenue of $601 million with strong growth and later completed the Astria Therapeutics acquisition on Jan 23, 2026. It also issued smaller items like inducement grants and a J.P. Morgan conference appearance. Today’s inducement grants continue this pattern of incremental corporate updates following larger strategic steps.

Market Pulse Summary

This announcement details standard inducement equity awards—stock options and RSUs—granted to 24 new...

Analysis

This announcement details standard inducement equity awards—stock options and RSUs—granted to 24 new employees under Nasdaq Listing Rule 5635(c)(4), with options for 251,150 shares and RSUs for 368,550 shares at a $6.63 exercise price. It follows recent strategic milestones, including the Astria acquisition on Jan 23, 2026 and strong ORLADEYO revenue for 2025. Investors may watch how ongoing hiring, integration, and prior regulatory wins translate into future operating performance.

Key Terms

nasdaq listing rule 5635(c)(4), stock options, restricted stock units, rsus, +2 more

6 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"granted 24 newly-hired employees stock options to purchase an aggregate of 251,150"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

restricted stock units financial

"and restricted stock units (RSUs) covering an aggregate of 368,550 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"restricted stock units (RSUs) covering an aggregate of 368,550 shares"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

exercise price financial

"The options have an exercise price of $6.63 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equity incentive plan financial

"subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

AI-generated analysis. Not financial advice.

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 24 newly-hired employees stock options to purchase an aggregate of 251,150 shares, and restricted stock units (RSUs) covering an aggregate of 368,550 shares, of BioCryst common stock. The options and RSUs were granted as of February 2, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $6.63 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

FAQ

What did BioCryst (BCRX) announce on February 5, 2026 about employee equity grants?

BioCryst announced inducement grants of options and RSUs to 24 new employees on February 2, 2026. According to the company, the awards total 251,150 options and 368,550 RSUs provided as material inducements to employment under Nasdaq Rule 5635(c)(4).

What are the key terms of the stock options granted by BioCryst (BCRX)?

The options have an exercise price of $6.63 and a 10-year term. According to the company, the $6.63 price equals the closing price on the grant date and each option vests in four equal annual installments starting one year after the grant.

How do the BioCryst (BCRX) RSUs and options vest for new hires?

The awards vest in four equal annual installments beginning on the one-year anniversary of the grant. According to the company, vesting is contingent on the new employee's continued service and follows the terms of the Inducement Equity Incentive Plan.

How many shares were covered by the inducement awards announced by BioCryst (BCRX)?

The inducement awards covered a combined 619,700 shares between options and RSUs. According to the company, that total comprises 251,150 stock options plus 368,550 restricted stock units granted on February 2, 2026.

Why were the equity awards issued under Nasdaq Listing Rule 5635(c)(4) for BioCryst (BCRX)?

The awards were issued as inducements material to each employee entering employment with BioCryst. According to the company, grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) which permits inducement awards for newly hired employees.